Skip to main content
. 2022 Jun 16;9(23):2201895. doi: 10.1002/advs.202201895

Figure 6.

Figure 6

cGAMP/E7‐loaded nanovaccines (NVs) mediated robust immunotherapy in combination with αPD‐1 in TC‐1 tumor. A) Study design of TC‐1 combination immunotherapy in syngeneic C57Bl/6 mice. Vaccine: 10 nmole cGAMP and 20 µg antigen, s.c. administration at mouse tail base on days 7, 13, 19; αPD‐1: i.p. administration, 200 µg, on days 7, 10, 13, 16, 19. B,C) TC‐1 tumor growth curves (B) and the tumor weights at the end of study on day 28 (C). D) Kaplan–Meier mouse survival curves. E) Spleen/body weight ratios of mice at day 28 after treatment. F) Mouse body weights during the course of treatment. Data represent mean ± SEM; ns: not significant, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 (one‐way ANOVA with Dunnett test).